Clinical Case Scenario

An elderly woman presents to the emergency room with generalized weakness, headache, and confusion. Her blood pressure is 220/105 mmHg. Physical examination reveals skin thickening of the extremities, facial telangiectasias, and decreased oral aperture. Laboratory studies reveal creatinine levels of 3.5 mg/dL, hemoglobin at 7.0 g/dL, a platelet count of 75,000/mm³, and lactate dehydrogenase at 700 U/L.

Wrong Answer: A. Amlodipine

Right Answer: B. Captopril

Explaination
This patient has malignant hypertension with scleroderma renal crisis (SRC), given:
● Severe HTN (220/105 mmHg) + encephalopathy (headache, confusion)
● Skin thickening, telangiectasias, microstomia (consistent with systemic sclerosis)
● Acute kidney injury (Cr 3.5 mg/dL)
● Microangiopathic hemolytic anemia (MAHA) (Hb 7.0, platelets 75k, elevated LDH)

Why Captopril?
● ACE inhibitors (e.g., captopril, enalaprilat) are first-line for SRC and significantly reduce mortality.
● They rapidly control BP and improve renal blood flow.
● Oral captopril is preferred in stable patients due to its rapid onset.

Why not the Other options?
● A. Amlodipine (CCB): Not first-line for SRC; ACE inhibitors are superior.
● C. Eculizumab: Used for atypical HUS, not SRC.
● D. Heparin: Not indicated (no evidence of thrombosis).
● E. Plasmapheresis: Used for TTP/HUS, not SRC.

Therefore, for this patient, Immediate Management would be:
1. Start captopril (or IV enalaprilat if unstable).
2. Admit to ICU for BP monitoring (goal: gradual reduction).
3. Avoid steroids (can worsen SRC).
4. Consider dialysis if severe AKI

Clinical Pearls:
Scleroderma Renal Crisis (SRC)

Epidemiology & Risk Factors
- SRC occurs in 12% of diffuse systemic sclerosis vs. 2% of limited systemic sclerosis.
- Major high-risk features are rapid skin progression, new anemia, pericardial effusion, or anti-RNA polymerase III antibodies.

Key Clinical Presentation
1. Hypertensive emergency(often >150/90 mmHg) + rapid renal decline (Cr ↑, proteinuria, hematuria).
2. MAHA (↑LDH, ↓Hb, ↓platelets) in >50% but no coagulopathy.
3. Extrarenal manifestations: - **Retinopathy, encephalopathy** (hypertensive).
- **Pulmonary edema** (salt/water retention).
- **Cardiac involvement** (myocarditis, arrhythmias) → **poor prognosis**.
Management
First-line drugs are ACE inhibitors (captopril, enalaprilat), which reduce mortality from >90% to ~30%. Aim for a BP reduction of ↓SBP by 20 mmHg and ↓DBP by 10 mmHg every 24h. Add CCBs (amlodipine) only after maximizing the ACEi dose. ARBs are an alternative, but ACEis are preferred.

Avoid: Steroids (may trigger SRC). Heparin, eculizumab, and plasmapheresis are not indicated for SRC.

Prognosis: Approximately 66% require initial dialysis, but 50% regain renal function (median 1 year). Continue ACEi, even if dialysis-dependent, due to potential for late recovery. Differential Diagnosis: Exclude TTP (treat with plasmapheresis) and aHUS (treat with eculizumab). SRC = MAHA + HTN + scleroderma features.

Wrong Answer: C. Eculizumab

Wrong Answer:D. Heparin

Wrong Answer:E. Plasmapheresis